These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 4080721)

  • 1. Electrophysiological effects of cholecystokinin: central dopaminergic systems.
    Wang RY; White FJ
    Prog Clin Biol Res; 1985; 192():95-103. PubMed ID: 4080721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased neuronal responsiveness to cholecystokinin and dopamine induced by lesioning mesolimbic dopaminergic neurons: an electrophysiological study in the rat.
    Debonnel G; de Montigny C
    Synapse; 1988; 2(5):537-45. PubMed ID: 2903570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microiontophoretic studies of the dopaminergic inhibition from the ventral tegmental area to the nucleus accumbens neurons.
    Akaike A; Sasa M; Takaori S
    J Pharmacol Exp Ther; 1984 Jun; 229(3):859-64. PubMed ID: 6726660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function.
    Vaccarino FJ; Rankin J
    Behav Neurosci; 1989 Aug; 103(4):831-6. PubMed ID: 2765186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholecystokinin potentiates dopamine-mediated behaviors in the nucleus accumbens, a site of CCK-DA co-existence.
    Crawley JN
    Psychopharmacol Bull; 1985; 21(3):523-7. PubMed ID: 4034868
    [No Abstract]   [Full Text] [Related]  

  • 7. Does cholecystokinin potentiate dopamine action in the nucleus accumbens?
    Wang RY; Hu XT
    Brain Res; 1986 Aug; 380(2):363-7. PubMed ID: 3756487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of A9 and A10 dopamine cells by the cholecystokinin-B antagonist LY262691: mediation through feedback pathways from forebrain sites.
    Rasmussen K; Howbert JJ; Stockton ME
    Synapse; 1993 Oct; 15(2):95-103. PubMed ID: 8259526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term haloperidol treatment on the responsiveness of accumbens neurons to cholecystokinin and dopamine: electrophysiological and radioligand binding studies in the rat.
    Debonnel G; Gaudreau P; Quirion R; de Montigny C
    J Neurosci; 1990 Feb; 10(2):469-78. PubMed ID: 2137531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microinjection of cholecystokinin into the rat ventral tegmental area potentiates dopamine-induced hypolocomotion.
    Crawley JN
    Synapse; 1989; 3(4):346-55. PubMed ID: 2740993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholecystokinin octapeptides alter the release of endogenous dopamine from the rat nucleus accumbens in vitro.
    Voigt M; Wang RY; Westfall TC
    J Pharmacol Exp Ther; 1986 Apr; 237(1):147-53. PubMed ID: 3958963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
    J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral interaction between endogenous opioids, CCK-8 and dopaminergic systems in the nucleus accumbens of rats.
    van Ree JM; Igarashi J; Király I
    NIDA Res Monogr; 1986; 75():323-6. PubMed ID: 2448632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons.
    White FJ; Wang RY
    Brain Res; 1984 May; 300(1):161-6. PubMed ID: 6145498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholecystokinin facilitates methamphetamine-induced dopamine overflow in rat striatum and fetal ventral mesencephalic grafts.
    Wang Y; Perng SL; Lin JC; Tsao WL
    Exp Neurol; 1994 Dec; 130(2):279-87. PubMed ID: 7867757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of cholecystokinin function in the rostral and caudal nucleus accumbens: differential effects on brain stimulation reward.
    Vaccarino FJ; Vaccarino AL
    Neurosci Lett; 1989 Feb; 97(1-2):151-6. PubMed ID: 2918999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor selectivity of cholecystokinin effects on mesoaccumbens dopamine neurons.
    Kelland MD; Zhang J; Chiodo LA; Freeman AS
    Synapse; 1991 Jun; 8(2):137-43. PubMed ID: 1882334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholecystokinin antagonist lorglumide reverses chronic haloperidol-induced effects on dopamine neurons.
    Jiang LH; Kasser RJ; Wang RY
    Brain Res; 1988 Nov; 473(1):165-8. PubMed ID: 3208120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholecystokinin modulation of locomotor behavior in rats is sensitized by chronic amphetamine and chronic restraint stress exposure.
    Wunderlich GR; Rotzinger S; Bush DE; DeSousa NJ; Vaccarino FJ
    Brain Res; 2004 Mar; 1001(1-2):95-107. PubMed ID: 14972658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
    Meltzer LT; Christoffersen CL; Serpa KA; Razmpour A
    Synapse; 1993 Feb; 13(2):117-22. PubMed ID: 8446920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.